Author: Customer Service
WILMINGTON, Del., Nov. 20, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the pricing of its underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase 22,873,779 shares of common stock. The shares of common stock are being sold at an offering price of $1.45 per share, and the pre-funded warrants are being sold at an offering price of $1.449 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. In addition, Inhibikase has granted the underwriters a 30-day option to purchase up to an additional...
Bread Financial Announces Pricing of an Offering of Depositary Shares Representing Interests in Its Series A Preferred Stock
Written by Customer Service on . Posted in Public Companies.
COLUMBUS, Ohio, Nov. 20, 2025 (GLOBE NEWSWIRE) — Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced today the pricing of its previously announced underwritten public offering of depositary shares (the “Depositary Shares”), each representing a 1/40th interest in a share of its Non-Cumulative Perpetual Preferred Stock, Series A, par value $0.01 per share (the “Series A Preferred Stock”), with a liquidation preference of $25 per Depositary Share (equivalent to $1,000 per share of Series A Preferred Stock).
The Company expects to apply to list the Depositary Shares on The New York Stock Exchange.
The closing of the offering of the Depositary Shares is expected to occur on November 25, 2025, subject to the satisfaction of customary closing conditions, and is expected to result in approximately...
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Written by Customer Service on . Posted in Public Companies.
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program
The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class team
VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) — NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus...
Montauk Metals Announces Assignment into Bankruptcy
Written by Customer Service on . Posted in Public Companies.
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /
TORONTO, Nov. 20, 2025 (GLOBE NEWSWIRE) — Montauk Metals Inc. (TSX-V: MTK) (the “Company” or “Montauk”) filed a corporate assignment into bankruptcy pursuant to the Bankruptcy and Insolvency Act (Canada) (the “BIA”). The filing comes after the Board was unable to reach a settlement with its creditors.
The Fuller Landau Group Inc. has been appointed as the Licensed Insolvency Trustee (the “Trustee”) under the bankruptcy proceedings. Montauk’s three (3) directors and officers resigned immediately prior to the bankruptcy proceedings.
All further matters will be handled by the Trustee. The Trustee will administer the process of distributing any realizable assets to proven creditors, which consist of cash balances which are less than...
AlphaTON Capital (Nasdaq: ATON) Issues Shareholder Update on Balance Sheet Assets and Strategic Ecosystem Expansion Clarification and Correction
Written by Customer Service on . Posted in Public Companies.
AlphaTON Capital has No Equity Line Financing with ATW Partners or any other provider. ATW Partners is not an investor whatsoever. AlphaTON Capital has never drawn down the entire Bitgo facility and has continued to manage leverage at 7% Debt to Equity Ratio.
New York, NY, Nov. 20, 2025 (GLOBE NEWSWIRE) — AlphaTON Capital Corp. (Nasdaq: ATON) (“AlphaTON” or the “Company”), a specialized digital asset technology company focused on the Telegram ecosystem, today issued a comprehensive update to shareholders regarding its balance sheet composition and strategic initiatives executed since the closing of its PIPE funding on September 25, 2025.
The Company has aggressively deployed capital into high-conviction assets, establishing a robust foundation for long-term growth through a three-pillar strategy: Treasury Accumulation
Network...
ECD Automotive Design Reports Third Quarter 2025 Financial Results, Highlighting Product Diversification, Cost Reductions, and Operational Efficiency Initiatives
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Product Lineup Now Includes Bespoke Porsche 911 Builds and Modern Defender & INEOS Grenadier Enhancements
KISSIMMEE, Fla., Nov. 20, 2025 (GLOBE NEWSWIRE) — ECD Automotive Design, Inc. (“ECD” or the “Company”) (NASDAQ: ECDA), the world’s largest Land Rover and Jaguar restoration company known for its custom luxury builds, including bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs and Toyota FJs, announced today its financial results for the third quarter ended September 30, 2025.
Management will host an earnings call and webcast on Monday, November 24, 2025 at 4:30 PM Eastern Time.
Third Quarter HighlightsRevenue was $5.8 million in the third quarter of 2025, compared to $6.4 million in the third quarter of 2024.
Gross loss was $1.7 million in the third quarter of 2025, compared to gross profit of $2.0 million...
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
Written by Customer Service on . Posted in Public Companies.
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs.
Dr John Levine, Chair of the BMT CTN Steering...
Faraday Future Completes Formation of “FFAI+AIXC” Dual-Flywheel, Dual-Bridge, and Dual-Listed Company System; Its Majority Owned Crypto Company Renamed as AIxCrypto (Nasdaq: AIXC)
Written by Customer Service on . Posted in Public Companies.
This represents an important step in advancing the “FFAI + AIXC” dual-flywheel, dual-bridge, and dual-listed company framework and supports the ongoing development of EAI + Crypto initiatives aimed at bridging Web2 and Web3.
FFAI will continue advancing its EAI ecosystem while progressing toward key product milestones, including the first FX Super One pre-production vehicle coming off the U.S. line by year-end and the first delivery in the UAE on November 27.
AIxC could benefit FFAI across five key areas: financing, asset, technology and business, users, and valuation.
FFAI and AIxC could work together to jointly advance the on-chain registration and verification of EAI EV assets and accelerate the development of integrated EAI + real-world asset (“RWA”) products that connect vehicle data, blockchain technology, and new digital-asset...
BioSyent Releases Financial Results for Q3 and YTD 2025
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September 30, 2025. Key highlights include:(CAD)
Q3 2025
% Change vs.Q3 2024
YTD 2025
% Change vs.YTD 2024
Trailing Twelve Months (TTM) Sept 30, 2025
% Change vs.TTM Sept 30, 2024Canadian Pharma Sales
9,864,254
+19%
28,351,130
+16%
36,897,581
+14%International Pharma Sales
1,153,742
+94%
3,134,572
+316%
3,311,306
+310%Legacy Business Sales
1,203,808
+83%
1,894,358
+73%
1,967,857
+48%Total Company Sales
12,221,804
+28%
33,380,060
+27%
42,176,744
+22%EBITDA¹
3,632,399
+27%
9,594,195
+35%
11,835,307
+35%Net Income After Taxes (NIAT)
2,682,340
+16%
7,020,444
+24%
8,633,638
+21%Fully Diluted EPS
0.23
+19%
0.61
+28%
0.75
+25%
Return...
BioSyent Declares Fourth Quarter 2025 Dividend
Written by Customer Service on . Posted in Dividend Reports And Estimates.
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.05 per common share, payable in Canadian Dollars on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. This fourth quarter 2025 dividend compares with the third quarter 2025 dividend of $0.05 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on...
